Management of 2×2cm Thrombus on Interatrial Septum After ASD Closure
Initiate therapeutic anticoagulation immediately with either unfractionated heparin or low molecular weight heparin, transitioning to warfarin for at least 3-6 months, with close echocardiographic surveillance to document thrombus resolution.
Rationale and Clinical Approach
This represents a device-related thrombotic complication following ASD closure, which while rare in pediatric populations, requires aggressive management to prevent catastrophic embolic events (stroke, pulmonary embolism, or paradoxical embolism). A 2×2cm thrombus is substantial and poses significant embolic risk.
Immediate Management Steps
Anticoagulation is the primary treatment strategy:
Start therapeutic anticoagulation immediately with either:
- Unfractionated heparin (UFH) with goal aPTT 1.5-2.5× control, OR
- Low molecular weight heparin (LMWH) at therapeutic dosing
Transition to warfarin with target INR 2.0-3.0 for sustained anticoagulation 1
Duration: Minimum 3-6 months, potentially longer depending on thrombus resolution and underlying risk factors [@1,2,3@]
Critical Diagnostic Considerations
Before proceeding, evaluate for underlying thrombophilia:
- This is essential, as undiagnosed hypercoagulable states dramatically increase recurrence risk 2
- Test for: Factor V Leiden, prothrombin gene mutation, protein C/S deficiency, antithrombin deficiency, antiphospholipid syndrome
- Genetic testing may reveal mutations (e.g., PROC gene) that explain the thrombotic event 3
The presence of a large thrombus in this setting suggests:
- Inadequate antiplatelet prophylaxis post-procedure
- Incomplete device endothelialization
- Underlying thrombophilic disorder
- Possible residual shunt preventing complete endothelialization [@1,2@]
Monitoring Strategy
Serial echocardiographic surveillance is mandatory:
- Perform transesophageal echocardiography (TEE) initially for detailed characterization
- TEE is superior to transthoracic echo for visualizing device-related thrombi 4
- Repeat imaging every 2-4 weeks to document thrombus resolution
- Case reports demonstrate complete thrombus resolution with anticoagulation alone [@7,10@]
Surgical Consideration
Reserve surgical thrombectomy for specific scenarios:
- Thrombus remains mobile and highly embolic despite anticoagulation
- Evidence of ongoing embolization (new stroke, PE) despite therapeutic anticoagulation
- Failure of thrombus to resolve after 3-6 months of adequate anticoagulation
- Hemodynamic compromise
The literature supports medical management as first-line, with successful thrombus resolution documented in multiple case reports [@7,9,10@]. Surgery carries its own risks and should be reserved for refractory cases [@9,11@].
Common Pitfalls to Avoid
Do not use thrombolysis as first-line therapy - While one case report describes successful thrombolytic treatment 1, the risk of fragmentation and massive embolization (both systemic and pulmonary) makes this approach dangerous, particularly with a large straddling thrombus 5.
Do not assume standard 6-month antiplatelet prophylaxis is sufficient - The guidelines recommend aspirin for 6 months post-ASD closure [@1,2,3@], but once thrombosis has occurred, full anticoagulation is required, not antiplatelet therapy alone.
Do not discontinue anticoagulation prematurely - If thrombophilia is identified, lifelong anticoagulation may be necessary 2. Even without identified thrombophilia, continue anticoagulation until complete thrombus resolution is documented and consider extended therapy.
Long-term Management
After thrombus resolution:
- If thrombophilia identified: Lifelong anticoagulation 2
- If no thrombophilia: Consider extended antiplatelet therapy beyond standard 6 months, particularly if residual shunt present [@1,2@]
- Maintain surveillance imaging at 6-12 month intervals, as very late thrombosis (even decades later) has been reported 4
Key Clinical Pearl
The 2013 AHA guidelines note that when complete defect closure is not achieved (residual shunt), complete endothelialization may not occur, and many experts continue thromboprophylaxis beyond 6 months due to ongoing paradoxical embolus risk [@1,2,3@]. This principle applies even more strongly when thrombosis has already occurred.